Identification of dimethyl 2,2’-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy))diacetate (TAJ4) as antagonist of NEK-Family: a future for potential drug discovery Authors: Mubashir Aziz, Syeda Abida Ejaz, Pervaiz Ali Channar, Ali G Alkhathami, Tahir Qadri, Zahid Hussain, Mumtaz Hussaain, Rabail Ujan Published: 2024 ABSTRACT AbstractThe purpose of the current study was to analyze and validate the existing gap in knowledge, by conducting a differential expression analysis and validation of NEK6, NEK7, and NEK9 in breast, cervical, and glioblastoma cancer and targeting these proteins through development of novel site specific inhibitor with favorable pharmacokinetic and safety profile, using open-source databases. The analysis revealed that the targeted kinases were overexpressed in all three types of cancer. Their expression was significantly linked to overall survival rates, which suggests that they play a major role in the development and progression of these cancers. After, having the prognostic importance of These findings provided a rationale for synthesizing novel compound i.e., dimethyl 2,2’-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy))diacetate (TAJ4)), capable of effectively targeting these proteins using in-vitro cytotoxicity assays and comprehensive computational approaches. Then the inhibitory potential of TAJ4 was evaluated against cell lines of the respective cancers (HeLa cells, MCF-7 cells, and Vero cells). The growth inhibitory values (GI50) suggested that TAJ4 exhibited strong inhibitory potential towards MCF-7 cells (GI50 = 3.18 ± 0.11 µM) in comparison to the HeLa cell line (GI50 = 8.12 ± 0.43 µM), surpassing that of standard drugs. Furthermore, in-silico investigations, including density functional theory (DFT) calculations and molecular docking studies, revealed a substantial reactivity profile of TAJ4, with promising molecular interactions against NEK7, NEK9, TP53, NF-KAPPA-B, and caspase-3 proteins. Further investigation using in-vitro and in-vivo approaches is recommended to fully establish the therapeutic efficacy and safety profile of TAJ4.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-024-13269-4.Keywords: NIMA related kinases, Expression analysis, Benzotriazole derivative, Single-crystal analysis, Cytotoxicity assay, In-silico studies Introduction Cancer is still one of the main causes of death in the world. Breast, cervical, and glioblastoma cancers contribute to an enormous percentage of the global cancer burden. Breast cancer and cervical cancer are two of the most prevalent cancers affecting women globally, with breast cancer leading in incidence and cervical cancer ranking fourth [1]. The common sites for invasive breast cancer to metastasize are the lung, liver, bone and brain while for cervical cancer, the frequent metastatic sites are the lungs, extra-pelvic nodes, liver and bones [2]. Understanding these metastatic patterns aids in surveillance strategies and therapeutic approaches, helping tailor treatments to improve patient outcomes and manage symptoms effectively [3]. Because the development of cancer is so complicated, it’s crucial to find specific biomarkers that can help with early diagnosis, prognosis, and the development of targeted therapies [4]. The search for novel and effective cancer biomarkers and therapeutic targets is a major focus of oncological research, motivated by the urgent need to improve diagnostic precision and treatment outcomes. In this context, the Never in Mitosis Gene A (NIMA)-related kinases (NEKs) have emerged as critical players in cell cycle regulation and have been implicated in the tumorigenesis of various cancers including breast and cervical cancers [5]. Among these, NEK2, NEK6, NEK7, and NEK9 have garnered attention for their potential roles as biomarkers and therapeutic targets. NEK2, NEK6, NEK7, and NEK9 are serine/threonine kinases involved in the regulation of spindle assembly and mitotic progression [6]. Aberrant expression of these kinases has been associated with the disruption of cell cycle checkpoints, leading to genomic instability and cancer progression. Among different NEKs, NEK7 has been identified as a key player in the progression of various cancers, including pancreatic, cervical, gastric, and hepatocellular carcinoma. Its overexpression is correlated with poor prognosis, indicating its potential as a biomarker for these cancers [7, 8]. NEK7 also interacts with components of the immune response, such as the NLRP3 inflammasone (NOD-, LRR- and pyrin domain-containing protein 3), which is involved in inflammatory processes and may influence cancer progression [9]. Along with NEK7, NEK6 has potential role in mitotic cell division which is phosphorylated and activated by NEK9 [10]. Like NEK7, NEK6 also play potential role in the progression of different cancers and its specific role in breast, cervical, and glioblastoma cancers is still unexplored. But its role in mitotic progression and its activation by NEK9 suggest that it may also be significant in the prognosis and diagnosis of targeted cancers and other associated malignancies. The third targeted protein i.e., NEK9 has been shown to be associated with distant metastasis in various cancer, serving as an independent predictive factor for the aggressive cancer behavior [7]. Like NEK7, NEK6 and NEK9, NEK2 is very closely related to NEK6 and NEK9, has been found to be overexpressed in breast cancer and is implicated in poor recurrence-free survival and overall survival [11]. NEK2’s role in various cancers, including cervical squamous cell carcinoma and endocervical adenocarcinoma, has been highlighted with a significant fold change in expression, suggesting that NEK family members may have a broad impact on cancer prognosis and diagnosis [8, 12]. The upregulation of these kinases in all three forms of cancer and their notable correlation with overall survival rates indicate their significant involvement in the emergence and propagation of cancer. A comprehensive analysis of their expression patterns and functional roles in breast, cervical, and glioblastoma cancers is still remained unexplored and therefore there is an urgent need of exploration of expression pattern of theses NEKs in targeted cancers. The differential expression patterns of NEKs proteins will not only acts as a possible indicator for these cancers but also offers a justification to produce novel compounds that can specifically target these enzymes. Indeed, developing potent and selective inhibitors targeting NEK (NIMA-related kinase) enzymes could significantly advance therapeutic strategies for NEK-associated cancers [13]. Prior research has revealed that only a limited number of compounds have been identified as inhibitors of the NEK family of kinases, specifically NEK7 and NEK6. The limited availability of selective and specific inhibitors has necessitated the development of new compounds that can effectively target the putative biomarkers associated with these malignancies. The Figure S1 (supplementary data) displays a few previously reported NEK6 and NEK7 inhibitors [14] . The main objective of the present investigation is to address the existing gap in knowledge, by conducting an differential expression analysis and validation of NEK6, NEK7, and NEK9 in breast, cervical, and glioblastoma cancer and targeting these proteins through development of novel site specific inhibitor with favorable pharmacokinetic and safety profile. Initially, the expression profiling of NEK6, NEK7 and NEK9 was executed by utilizing the various open source databases including UALCAN platform (http://ualcan.path.uab.edu/), which is grounded in TCGA OMICS data. Whereas, benzotriazole scaffold based potential inhibitor i.e., dimethyl 2,2’-((methylenebis(2-(2 H-benzo[d][1,2,3]triazol-2-yl)−4-(2,4,4-trimethylpentan-2-yl)−6,1phenylene))bis(oxy))diacetate (TAJ4) was synthesized through multiple synthetic pathways (Scheme 1).The Benzotriazole scaffold was initially synthesized by the combination of acetylenes with azides via 1,3 dipolar cycloaddition reaction [15]. This reaction requires a high energy of activation and produces 1,4- and 1,5-regioisomers but copper catalyzed (CuAAC) version of this reaction gives 100% regioselectivity producing only the 1,4- disubstituted regioisomer along with substantial yield under mild conditions [16]. Synthesis of Dimethyl 2,2'-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)−4-(2,4,4-trimethylpentan-2-yl)−6,1 phenylene))bis(oxy))diacetate (TAJ4) The Benzotriazole scaffold based derivative was selected as it is believed as a privileged class of compound for its numerous bioactivities and have drawn unique attention for their prominent medicinal applications [17] including antibacterial [18], cytotoxic [19], antiproliferative [20], antituberculosis [21], anti-HIV [22], and antioxidant [23] as shown in Figure S2 provided in supplementary data. Moreover, the production of benzotriazole has broadly been studied for its medicinal applications such as, neuroprotective agents [24], anti-anxiety [25], antichagasic agents [26], antileishmanial [27], anti-inflammatory [28] and antibacterial [29]. After synthesizing the Benzotriazole derivative (TAJ4), the inhibitory potential was evaluated via in-vitro cytotoxicity assays against cancer cell lines i.e., one breast cell line MCF-7 cell line (HTB-22™) and one human cervical cancer cell line (the HeLa cell line and the CRM-CCL-2™). Moreover, the role of the synthesized compound TAJ4 against the targeted cancers was justified using different computational approaches, revealing its significant efficacy against both cancers along with the role in metastasis as well. The therapeutic potential of the TAJ4 is shown by the fact that it is able to outperform conventional chemotherapeutic drugs like cisplatin and doxorubicin throughout treatment. Further elucidation of the reactivity profile of TAJ4 and its molecular interactions with NEK kinases is provided by the in-silico investigations via density functional theory (DFT) calculations, molecular docking studies, and MD simulations. The significant binding affinity of TAJ4 against NEK2, in particular, suggests its potential as a therapeutic agent, warranting further investigation. Experimental Materials and methods Synthesis protocol To a stirred solution of Initially 100 mg (0.152 mmol) of 6,6’-methylenebis(2-(2 H-benzo[d][1,2,3]triazol-2-yl)−4-(2,4,4- trimethylpentan-2-yl)phenol) (1) was allowed to stirred in 15 ml acetone along with the addition of 51 mg (0.0364 mmol) K2CO3. After few minutes, the addition of 0.04 ml (0.395 mmol) of methyl 2-chloroacetate was carried out in dropwise manner. The reaction mixture was heated at reflux temperature of acetone for 18 h. The progress of the reaction was monitored using TLC in which the complete consumption of the reactant i.e., 6,6’-methylenebis(2-(2Hbenzo[d][1,2,3]triazol-2-yl)−4-(2,4,4-trimethylpentan-2-yl)phenol) (1) was also observed. On completion, the reaction mixture was washed out thrice with dichloromethane (DCM)/water (H2O) followed by drying using magnesium sulphate (MgSO4). At the end, the solvents were allowed to evaporate on rotary evaporator and crude product was purified through silica gel using column chromatography where n-Hexane and Dichloromethane (8:2, v/v) were used to afford the purified dimethyl 2,2’-((methylenebis(2-(2 H benzo[d][1,2,3] triazol-2-yl)−4-(2,4,4trimethylpentan-2-yl) 6,1phenylene))bis(oxy))diacetate (3) in excellent yield. Characterization data of Benzotriazole (TAJ4) An open capillary approach was utilized in order to evaluate the melting points, and a Gallenkamp melting point apparatus (MP-D) was utilized for this purpose. A spectrometer with the model number FTS 300 MX from the Bruker FT-IR Bio-Rad-Excalibur Series was utilized in order to carry out the identification of the functional groups. In order to get the 1HNMR and [13] C NMR spectra, a Bruker 300 MHz NMR spectrometer was utilized, and the solvents that were utilized were deuterated DMSO and CDCl3. Using an LC Agilent system 1200 series equipment, the purity of the substance was determined using high-performance liquid chromatography-mass spectrometry (HPLC-MS), and the elemental analyses were carried out with an LECO183 CHNS analyzer. The FTIR 1HNMR and [13]C NMR spectra’s are provided in supplementary file (Figure S3-S5). Yield: 72%, Rf: 0.44 (EtOAc: Petroleum ether 1:9); FT-IR (KBr, cm−1): 2997.7 (Aromatic -CH stretch), 2951.3 (Aliphatic -CH stretch), 1762.6 (-C = O stretch), 1582.6, 1556.1 (C-C stretches in ring),1198.7 (C-N stretch), 746.8 1 (Aromatic C-H “oop”), 1HNMR: (300 MHz, CDCl3): δ 7.94 (dd 4 H J = 6.6 Hz, 3 Hz), δ 7.65 (S 2 H), δ 7.43 (dd 4 H J = 6.6 Hz, 3 Hz), δ 7.29 (S 2 H), δ 4.45 (S 2 H), δ 4.26 (S 4 H), δ 3.56 (S 6 H), δ 1.70 (S 4 H), δ 1.32 (S 12 H), δ 0.73 S (S 18 H). Anal. Calcd. For C47H58N6O6 : C, 70.30; H, 7.28; N, 10.47. Found: C, 70.34; H, 7.26; N, 10.45. HRMS (ESI): m/z Calcd for [C47H58N6O6 + H] + 802.4418, Found 802.4422 EI, m/z [% rel. int.]: 802.6 [M+, 31], 731.1 [47.78], 671.3 [24.03], 497.1 [12.34], 380.0 [11.77], 330.0 [53.28], 263.9 [72.75], 177.0 [7.26], 57.0 [100]. Biological activities MTT Assay (cell viability assay) The compound TAJ4 underwent a comprehensive assessment of its anticancer efficacy against two distinct human cancer cell lines, namely HeLa, a cell line associated with cervical cancer, and MCF-7, a cell line associated with breast cancer. The present evaluation was based on the established methodology proposed by Mosmann (1983) and Nik and Otto (1990), as described in our previous studies [30–32]. The study was conducted using 96-well flat-bottom plates, with a volume of 90 µL of media and a seeding density of 10 × 104 cells per well. A volume of 10 µL (100 µM) of TAJ4 solution was introduced into each well, followed by a 24-hour incubation period at a temperature of 37 °C and a CO2 concentration of 5%. 10 µL of the standard drug (cisplatin) was added to the positive control well, whereas 100 µL of cells medium (without chemical) was added to the negative control well. Subsequently, 10 µL of MTT reagent was added to each well and allowed to incubate for 4 hours at a temperature of 37 °C. Subsequently, a volume of 100 µL of a 10% sodium dodecyl sulfate solution was introduced to aid in the solubilization of crystals. The resulting mixture was then kept at the room temperature for a duration of 30 min, with intermittent agitation. The optical density was determined to be 570 nm, while the background absorbance was measured at 630 nm. The experiment was conducted three times, and the results were reported as percentages of growth inhibition, as previously explained [33]. Statistical analysis Data is presented in the form of % growth reduction in tables along with standard error of means and in graphs using One-way ANOVA using Prism statistical software package (GraphPad Software, Inc., La Jolla, CA, USA) with P < 0.005* which was considered statistically significant. The IC50 values were also calculated by fitting the sigmoidal dose response model using GraphPad Software version 5.0. In-silico investigations Differential expression analysis and methylation profiling In the realm of oncological research, the present study meticulously employed a suite of public databases to scrutinize and substantiate the expression patterns of NEK6, NEK7, and NEK9 within the context of three divergent cancer types: breast cancer, cervical cancer, and brain tumors. This investigation extended to the examination of the interplay between the expression of these proteins and their corresponding genes across the specified cancer types. Utilizing the UALCAN platform [34] (http://ualcan.path.uab.edu/), which is grounded in TCGA OMICS data [35], the study conducted expression and methylation profiling for NEK6, NEK7, and NEK9, encompassing the aforementioned cancer varieties. The UALCAN database’s default parameters facilitated the application of the Student’s t-test, with a p-value threshold of less than 0.05 earmarked as the benchmark for statistical significance. Further analytical rigor was applied through the GEPIA 2 database [36] (http://gepia2.cancer-pku.cn/), which served as a tool for correlation analysis, overall survival (OS) metrics, and the elucidation of isoform specifics for the genes of interest within the three cancer types under study. The GEPIA 2’s default settings were harnessed, and the ANOVA test [37] was employed as the differential method, thereby reinforcing the diagnostic and prognostic utility of the targeted genes. In pursuit of biomarker discovery, the study traversed the TCGA and GTEx databases [38], seeking to unearth the biomarker potential of NEK6, NEK7, and NEK9 in breast, cervical, and glioblastoma cancers. This exploration was pivotal in identifying the relevance of these genes as biomarkers in the oncological landscape. The Human Protein Atlas (HPA) [39] (http://www.proteinatlas.org/) was instrumental in the analysis of the proteomic expression levels of NEK6 and NEK7 in both cancerous and normal tissues from the breast, cervix, and brain. The proteomic expression was meticulously categorized based on staining intensity, ranging from non-detectable to high. Lastly, the study delved into the protein-protein interaction (PPI) network pertaining to the genes in question, utilizing the STRING database (https://string-db.org/) [40]. A low confidence value of 0.15 was established as the principal parameter for the construction of the PPI model, offering insights into the intricate web of interactions between these proteins. Density function theory studies (DFTs) The present study employed Density Functional Theory (DFT) [41] as a robust computational strategy for the determination of electronic structure and reactivity of the TAJ4 compound and facilitated. The DFT calculations facilitated the optimization of the ground state geometries [42] and the assessment of reactivity parameters for the TAJ4 compound, culminating in the acquisition of its stable conformation post the most energetically favorable descent [43]. The computational methodology hinged on the B3LYP functional, a hybrid correlation-functional, in conjunction with the 6-31G* basis set [44]. This particular basis set is instrumental in the accurate determination of electron density and chemical reactivity, as it provides a balanced trade-off between computational efficiency and the precision required for such evaluations. The choice of the B3LYP/6-31G* level of theory is predicated on its established reliability in capturing the essential quantum mechanical features necessary for a comprehensive understanding of molecular behavior. The computational procedures were executed using the Gaussian 09 software suite [45], a state-of-the-art program for electronic structure modeling. The initial configuration files were meticulously prepared, and the resultant output was visualized with the aid of GaussView 6.0 [46], a graphical interface that enhances the interpretability of computational results. The construction and significance of the basis set employed in this methodology are paramount. The basis set, a collection of functions used to describe the electronic orbitals of the atoms within a molecule, is a foundational component in DFT calculations. It determines the level of detail at which the molecular electronic structure is described and, consequently, influences the accuracy of the predicted chemical properties. The 6-31G* basis set, in particular, is a split-valence basis set with polarization functions that enhance its ability to model the anisotropic distribution of electron density, which is critical for the accurate depiction of reactivity parameters. Molecular docking analysis Molecular docking stands as a promising avenue for unraveling the mechanistic insights and binding patterns of small molecules with biological targets, thereby facilitating a deeper comprehension of their behavior within active site amino acid residues [47]. In the context of the present study, molecular docking analyses were conducted to visually depict the binding affinities between a newly synthesized compound and a spectrum of targeted proteins, including NEK2, NEK7, NEK9, TP53, NF-KAPPA-B, and caspase-3, leveraging their 3D crystal structures sourced from the Protein Data Bank [48] (www.rcsb.com, PDB IDs:2W5A, 2WQN, 3ZKE, 3DCY, 1NFI, and 3DEI). Prior to the docking analyses, meticulous preparations were undertaken to ensure the integrity and reliability of the protein structures. This involved the elimination of heteroatoms and water molecules, the addition of polar hydrogen atoms, the incorporation of Kollman charges, and the visualization and supplementation of missing amino acid residues, all conducted via MGL Tools [49]. Concurrently, the 3D structure of the newly synthesized compound was meticulously refined using ChemDraw 3D [50], culminating in the attainment of its most energetically stable configuration. The subsequent molecular docking endeavors were executed utilizing AutoDock’s [51] default genetic algorithm as the scoring function [52], with the grid box dimensions meticulously tailored to each targeted protein as discussed earlier [49]. For each target protein a 100 distinct configurations were obtained. The most stable pose with least binding energy was selected and subjected for 2D and 3D analysis to describe interactions. The Novel derivatives with better binding affinities towards target proteins can be synthesized from the outcomes of this current study. Furthermore, the robustness and reliability of the molecular docking protocol were rigorously validated to bolster the authenticity of the adopted methodology. This validation entailed the re-docking of the native ligand of the biological target within the activation loop of the protein, with the ensuing comparison of the Root Mean Square Deviation (RMSD) value between the native and regenerated poses. An RMSD value below 2 angstroms was the criterion set for deeming the docking methodology efficient, thereby ensuring the veracity of the docking analyses [53]. Molecular dynamic simulations Computational approaches known as Molecular Dynamic (MD) simulations enable the investigation of the strength of molecular interactions within docked complexes over a period of time [54]. The dynamic nature of protein-ligand complexes obtained from molecular docking was investigated using Nanoscale Molecular Dynamics (NAMD) software version 1.9.3 [55]. The software demonstrated strong binding affinity for the corresponding proteins. Initially, the CHARMM-GUI web server was utilized to produce the topology files for the simulations [56], where all molecules, including ligands and proteins, were characterized by CHARMM36 force field parameters subject to periodic boundary conditions [57, 58]. In order to simulate the normal physiological conditions, same method were used as discussed in our previously published articles [53], and production run was carried out for 50ns. The Various analytical metrics, including root-mean-square deviation (RMSD) and root-mean-square fluctuation (RMSF), were employed to assess the stability of the protein-ligand complex. The electrostatic interactions observed during MD simulations were taken into account using Particle Mesh Ewald summation method [59]. All output files were visualized using VMD 1.9.3 [60]. X-ray crystallography and structure refinement The crystallographic data for the TAJ4 compound were obtained using a Rigaku Oxford Diffraction Eos Gemini diffractometer with Cu K radiation (= 1.5418). Using the multi-scan absorption correction applied to the to the data, the structures were solved and refined using SHELX software packages [61], while ORTEP-3 [62] programs were employed in drawings. Uiso (H) = k X Ueq (C, N) constraints were applied to refine the geometric positions of hydrogen atoms at distances of 0.88 (for NH), 0.95 (for CH), and 0.98 (for CH3). For NH, CH, and CH3 hydrogens, k = 1.2 and 1.5 for CH3 hydrogens, respectively. Crystallographic data for the structure presented here has been deposited by the Cambridge Crystallographic Data Centre and is designated as supporting information, CCDC No. 2,149,670. You can request copies of the data by submitting an application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (www.ccdc.cam.ac.uk), or by fax at + 44 1223 336,033. Hirshfeld surface (HS) studies The investigation of Hirshfeld surfaces (HS) is often regarded as the most reliable approach for examining interactions within crystal structures [63]. The crystal structure of the TAJ4 molecule was analyzed using Crystal Explorer 17.5 to determine the intermolecular interactions [64] The Hirshfeld surface distance from the nearest nucleus was measured and represented by di and de, respectively, on both the inside and outside of the surface. Dnorm was used to indicate the normal contact distance. The colors white, blue, and red have been used to represent Dnorm. The input file is in CIF format and can be found in the supplementary material. Results and discussion Chemistry Dimethyl 2,2’-((methylenebis(2-(2 H-benzo[d][1,2,3]triazol-2-yl)−4-(2,4,4-trimethylpentan-2-yl)−6,1 phenylene))bis(oxy))diacetate afforded as white color solid through the combination of 6,6’-methylenebis(2- (2 H-benzo[d][1,2,3]triazol-2-yl)−4-(2,4,4-trimethylpentan-2-yl)phenol) (1) and methyl 2-chloroacetate (2) along with K2CO3 that used as base for deprotonation. Stirring of the reaction flask was kept on 75oC for 18 h as shown in Scheme 1. Obtained product (3) was characterized by 1HNMR, EI-MS, UV-visible and I.R spectroscopy. Results from 1HNMR spectroscopy were comparable as two singlets at δ 0.73 ppm and δ 1.32 ppm were seen for 18 H and 12 H protons.-CH2 protons of alkyl branch appeared at δ 1.70 ppm as singlet whereas -CH2 protons of acetate group arose at δ 3.56 ppm as singlet. Ether linkage -CH2 protons were seen as singlet at δ 4.26 ppm for the integration of 4 H while the -CH2 protons of the center point of molecule observed at δ 4.45 ppm. Aromatic region remained productive as it gave a singlet at δ 7.29 ppm for 2 H. A doublet of doublet at δ 7.43 ppm emerged with the J values 6.6 and 3 Hz for 4 H. Another signal appeared at δ 7.65 ppm as singlet with the integration of 2 H. A doublet of doublet was seen at a concentration of 7.94 parts per million for 4 H, accompanied with the J values of 6.6 and 3 Hz. By revealing M + at m/z 802.6, the mass spectrum provided evidence in support of the estimated mass. On the other hand, the fragmentation process resulted in the formation of the ions listed below. The neopentyl group was removed, which resulted in the formation of a fragment that was discovered at m/z 731.1. As a result of the exclusion of the acetate (acyl) group from compound 3, a fragment was also observed at m/z 671.3. On the other hand, the base peak was observed at m/z 57. There was a peak found in the infrared spectrum at 2951.3 cm−1, which corresponds to the C-H stretch of alkane. 2997.7 cm−1 is the frequency of the aromatic C-H stretch. However, the C-N stretch was observed at 1198.7 cm−1, while the C-C lengths (in ring) were exposed at 1556.1 cm-1 and 1582.6 cm-1. At a frequency of 746.8 cm−1, the aromatic C-H “oop” was discovered. A confirmation of the production of compound (3) was also provided by the XRD technique. The bond angle of compound (3) is 115.3 (2)0, and it is composed of two aromatic components that are coupled to one another through -CH2 carbon. The results demonstrate that molecules interact with one another through the production of hydrogen bonds, which are represented by the formula C – H.N. These bonds are responsible for the construction of an extended chain that is parallel to the axis. Consequently, each and every one of the facts that were presented acknowledged the production of compound (3). Cell viability assay Cancer cells are characterized by cellular sources; as a result they display special activities in a defined pathway. Therefore, human epithelial cervical cancer cells could play a different manner compared with breast cancer cells [65]. To determine the effect of TAJ4 on the viability of human breast cancer cells, the MTT assay was conducted. The effect of the compound TAJ4 on various cell lines, such as HeLa cells, MCF cells, and normal Vero cells, is illustrated in Table 1. The analysis focused on the percentage of development reduction. Viable HeLa cells were observed at 24 h and 48 h, at 44.9% and 23.8%, respectively. With regard to MCF cells, the results were extremely convincing, as only 4.9% of cells remained viable after 48 h. Additionally, 89.5% of healthy Vero cells retain viability after 48 h. According to these results, TAJ4 was cytotoxic to HeLa and MCF-7 cells but had the least effect on normal Vero cells. As shown in Table 1, a comparison was also made with the previously reported anticancer drugs doxorubicin and cisplatin. Observed reductions in cell viability in response to TAJ4 treatment provide evidence for its potential as an anticancer agent. Additional research is required to further understand the basic mechanisms of action and determine the effectiveness of the compound through in vivo studies (Figs. 1 and 2). Table 1Values for the % Growth reduction after 24 and 48 hours for HeLa and MCF-7 cellsCode%Growth reduction±SEMHeLa CellsMCF-7 CellsVero cellsAfter 24 hrAfter 48 hr After 24 hrAfter 48 hr After 24 hrAfter 48 hr TAJ-455.1±1.9876.2±3.1184.2±1.7895.1±2.888.22±0.6610.5±0.99Cisplatin79.2±1.4489.1±2.4485.2±2.1198.2±1.347.13±0.5412.1±1.04Doxorubicin69.2±1.9882.2±2.08 58.2±0.69 78.6±1.0610.3±0.8915.4±1.91 Values for the % Growth reduction after 24 and 48 hours for HeLa and MCF-7 cells The graphical presentation of % growth reduction exhibited by TAJ4, Cisplatin and Doxorubicin against two cancerous cell lines (HeLa and MCF-7) and normal cells (Vero) after 24 hrs and 48 hr. The results were calculated using one-way ANOVA and found statistically significant with P < 0.005* IC50 graphs of TAJ4 (a: HeLa; b: MCF-7), cisplatin(c: HeLa; d: MCF-7) and doxorubicin (e: HeLa; f: MCF-7) by fitting the sigmoidal dose response model using GraphPad Software version 5.0 An obvious distinction can be seen between the sensitivity of MCF-7 cells and HeLa-cells to TAJ4 as demonstrated by the findings presented in Table 2. Taking into consideration the findings, it would suggest that TAJ4 was more successful in inhibiting the proliferation of MCF-7 cells in contrast to HeLa cells. On account of the fact that HeLa cells are produced from cervical cancer and MCF-7 cells are derived from breast cancer, the difference in sensitivity may be attributed to the fundamental biological differences that exist between the cell lines. Table 2Values for the GI50 for HeLa and MCF-7 cellsCodeGI50 ± SEM (µM)HeLaMCF-7TAJ-48.12 ± 0.433.18 ± 0.11Cisplatin2.64 ± 0.134.63 ± 0.21Doxorubicin4.21 ± 0.227.32 ± 0.81 Values for the GI50 for HeLa and MCF-7 cells The different forms of cancer each have their own unique genetic and metabolic traits, which results in a variety of responses to the medications that are used to treat them. For MCF-7 cells and HeLa cells, the experimental values of GI50, 3.18 ± 0.11 and 8.12 ± 0.43 µM, respectively, could indicate differences in signaling pathways between these two cell types. Nevertheless, the MCF-7 cells showed a lower GI50 value, indicating that compound TAJ4 has significant potential for suppressing tumors and treating breast cancer. These findings were further confirmed through computational analysis, where the compound was docked with in the active pocket of all the targeted NEKs, found highly expressed in breast, cervical and brain cancer. From the in-vitro cell line data it was observed that this compound has more potential against breast cancer in comparison to the HeLa cells. The results were further supported by the in-silico investigation where the effect on the glioblastoma cancer was also explored and it was observed that the expression of targeted NEK isozyme is more in breast cancer and brain cancer and was found less in the cervical cancer. Therefore, based on these findings it can be suggested that TAJ4 can be the lead candidate for the treatment of breast cancer and its associated malignancies. In-silico investigations Differential expression analysis, promoter methylation profiling and protein-protein interactions (PPI) Publicly available databases have been instrumental in examining the expression levels of NEK6, NEK7, and NEK9 across three different types of cancer: breast cancer, cervical cancer, and glioblastoma. The GEPIA 2 platform served as the primary resource for conducting a comparative expression analysis of these kinases between cancerous and normal tissue samples. The comprehensive analysis indicated that all three NEK kinases—NEK6, NEK7, and NEK9—demonstrated increased transcriptional activity in cancer tissues [66]. Specifically, NEK6 was found to be significantly overexpressed in glioblastoma compared to normal brain tissue, with a statistically significant p-value of less than 0.05. The expression-log2 (TPM + 1) for NEK6 in glioblastoma was observed to vary between 4.8 and 6.4. NEK7 showed a more complex pattern of expression across the three cancer types. In glioblastoma, NEK7 levels were higher than in normal tissue, suggesting a potential role in the malignancy of this cancer type. However, in breast and cervical cancers, NEK7 expression did not differ significantly between cancerous and normal tissues, indicating a variable role of NEK7 in different cancer types. The expression profile of NEK9 was also thoroughly investigated. It was found to be upregulated in glioblastoma and breast cancer tissues. Interestingly, in cervical cancer, the expression of NEK9 was higher in normal tissues compared to tumor tissues, which could suggest a unique regulatory mechanism in this cancer type. The utilization of open-source databases such as GEPIA 2 has provided valuable insights into the expression patterns of NEK kinases in various cancers. The differential expression analysis underscores the potential of NEK6, NEK7, and NEK9 as biomarkers and therapeutic targets in cancer research. The significant overexpression of NEK6 in glioblastoma, the contrasting behavior of NEK7, and the unique expression profile of NEK9 in cervical cancer highlight the complexity of kinase regulation in cancer pathogenesis. The expression profiling of NEK6 and NEK7 is illustrated in Fig. 3(A) and (B) whereas expression profiling of NEK9 is provided in supplementary file (Figure S6). mRNA profiling of NEK6 and NEK7 in BRCA, CESC and GBM cancer and normal tissues. A Expression profiling of NEK6 in BRCA, CESC and GBM tumor vs normal tissues (*P<0.05) (B) Expression profiling of NEK7 in BRCA, CESC and GBM tumor vs normal tissues (C) Protein-protein interaction (PPI) network of NEK kinases Protein-protein interactions (PPIs) refer to the physical connections between protein molecules, playing crucial roles in various cellular processes, such as signal transduction, enzyme regulation, macromolecular complex formation, cellular transport, and cell cycle control. The investigation of PPIs is a significant research area in biology and medicine, offering valuable insights into disease mechanisms and the development of innovative therapeutic approaches. The interaction analysis suggests that NEK6, NEK7 and NEK9 are involved in interactions with several proteins, including RCC1L, GSDMD, BICD2, NLRP3, and PYCARD. This insight into NEK7’s protein interactions could provide valuable information for understanding its role in cellular processes and potential implications for disease mechanisms. Further research into these interactions may uncover novel pathways or targets for therapeutic intervention. PPI of three distinct kinases is illustrated in Fig. 3(C). Promoter methylation profiling of NEK6, NEK7 and NEK9 Promoter methylation is a pivotal epigenetic modification that plays a crucial role in the regulation of gene transcription and is a key determinant in the development of cancer. The current study delves into the relationship between promoter methylation levels and gene expression, particularly focusing on NEK6, NEK7, and NEK9 in breast cancer (BRCA), cervical cancer (CESC), and glioblastoma (GBM). Box plots in the study’s figures illustrate the methylation status of NEK6, NEK7, and NEK9 across the three cancer types. The plots labeled A, B, and C depict the promoter methylation of NEK6, NEK7, and NEK9 in BRCA tissues, respectively. Plots D, E, and F present the methylation levels in CESC, while G, H, and I represent the same for GBM tissues. The beta values, which range from 0 (no methylation) to 1 (hypermethylation), are plotted on the y-axis to indicate the degree of methylation. Beta values between 0.5 and 0.7 suggest hypermethylation, whereas values from 0.3 to 0.25 indicate hypomethylation. A threshold of P < 0.05 was established for significant correlation. The study found that variations in methylation levels directly influence the expression of the genes in question. Specifically, hypomethylation of NEK7 and NEK9 in BRCA is linked to the upregulation of these genes. In contrast, NEK6 showed an atypical pattern where hypermethylation is associated with increased gene expression, particularly in GBM tissues. This unexpected behavior warrants further investigation to understand the underlying mechanisms. In GBM, hypermethylation of NEK6 is also correlated with increased gene expression, suggesting a cancer-specific regulatory phenomenon. Additionally, in cervical cancer, the increased expression of NEK6, NEK7, and NEK9 is associated with hypomethylation, further emphasizing the complex relationship between methylation status and gene activity. Similarly, the impact of promoter methylation on gene expression in various clinicopathological parameters (race, age, gender) was calculated and analyzed. The significant association was found between promoter methylation and gene expression in various clinicopathological parameters. The detailed analysis and Figures of various clinicopathological parameter are provided in supplementary file (Figure S7-S9). These findings underscore the importance of promoter methylation as a biomarker for cancer prognosis and a potential target for therapeutic intervention. Understanding the distinct methylation patterns of NEK kinases in various cancers could lead to more precise and effective treatments. The intricate interplay between promoter methylation and gene expression in cancer highlights the significance of epigenetic modifications in tumorigenesis. The NEK family of kinases, with their varying methylation and expression profiles, presents a promising area for further research, with the potential to improve cancer diagnostics and treatment strategies. The detailed illustration of promoter methylation of NEK6, NEK7 and NEK9 is provided in Fig. 4. Promotor Methylation level of NEK6, NEK7 and NEK9 in BRCA, CESC and GBM. A Methylation level of NEK6 in BRCA, B NEK7 in BRCA (C) NEK9 in BRCA Prognostic value of NEK6, NEK7 and NEK9 Recent studies have focused on the prognostic significance of the NEK family of kinases, particularly NEK6, NEK7, and NEK9, in various cancer types. Kaplan-Meier plots have been utilized to evaluate the survival outcomes of patients with different expression levels of these proteins. Patients with high expression levels of NEK6 have been consistently associated with reduced overall survival (OS) and disease-free survival (DFS). This suggests that NEK6 could be a potential biomarker for poor prognosis in cancer patients. The hazard ratio (HR) for patients with high NEK6 expression was found to be 2, indicating a doubling of the risk of adverse outcomes compared to patients with lower NEK6 levels. The statistical significance of this association is underscored by a logrank p-value of 9.2e-10, which is highly indicative of a strong correlation. In the case of NEK7, its high expression in cancers such as breast cancer (BRCA), cervical cancer (CESC), and glioblastoma (GBM) has been linked to a significant reduction in overall survival. The HR for high NEK7 expression groups was 1.1, with a logrank p-value of 0.45 and a 95% confidence interval (CI), indicating a modest but statistically significant impact on survival. The expression of NEK9 has also been found to have prognostic value. High NEK9 expression groups exhibited a distinct decrease in survival, with an HR of 0.73, a logrank p-value of 0.00339, and a 95% CI. This suggests that NEK9 may play a complex role in cancer progression, and its lower HR compared to NEK6 and NEK7 indicates a different pattern of influence on patient survival. The findings on NEK kinases provide valuable insights for cancer research and potential therapeutic targets. The strong prognostic values associated with NEK6 and NEK7, in particular, highlight the need for further investigation into their roles in cancer biology and the development of targeted therapies. Figure 5 is illustrating the overall survival and disease free survival of patients with high expression of NEK6 (A, B), NEK7 (C, D) and NEK9 (E, F) respectively. Kaplein-meier plots representing relationship between NEK expression and overall survival duration in three distinct cancer type. A, B Prognostic value of NEK6 in BRCA, CESC and GBM (C, D) Prognostic value of NEK7 in BRCA, CESC and GBM (E, F) Prognostic value of NEK9 in BRCA, CESC and GBM Differential expression analysis of NEK6, NEK7 and NEK9 in 24 cancer subtypes (normal vs. tumor) The differential expression analysis conducted in this study investigated the expression patterns of NEK6, NEK7, and NEK9 in 24 cancer types compared to their respective normal tissues. It is noteworthy that NEK6 exhibited significant overexpression in glioblastoma (GBM), kidney renal cell carcinoma (KIRC), sarcoma (SARC), and skin cutaneous melanoma (SKCM). On the other hand, NEK7 was significantly expressed in normal breast cancer tissues (BRCA), glioblastoma (GBM), esophageal carcinoma (ESCA), sarcoma (SARC), and skin cutaneous melanoma (SKCM). It is worth mentioning that NEK7 expression was higher in normal tissues compared to tumor tissues. Regarding NEK9, it demonstrated significant expression in normal tissues of breast cancer (BRCA), bladder urothelial carcinoma (BLCA), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), sarcoma (SARC), and skin cutaneous melanoma (SKCM). The detailed expression profile of NEK6 and NEK7 is provided in Fig. 6 whereas expression profile of NEK9 in normal vs. tumor tissue is provided in supplementary file (Figure S6). Expression profile of NEK6 and NEK7 in 24 cancer subtypes. A Expression profile of NEK6 in 24 cancer subtypes (B) Expression profile of NEK7 in 24 cancer subtypes normal vs tumor The current study examined the differential expression of NEK6, NEK7, and NEK9 across various clinicopathological parameters, including race-based groups, gender, and age-based groups. The expression levels of these selected kinases were analyzed in breast, cervical, and brain tissues, with the expression values presented in TPM (transcripts per million). The analysis revealed that NEK6 exhibited high expression in breast tissues of Asian individuals, while NEK7 and NEK9 showed significant expression in normal and Caucasian populations, respectively. In terms of gender-based groups, NEK6 displayed high expression in female breast tissues, whereas NEK7 and NEK9 exhibited comparable expression levels in both female and male individuals. These findings suggest that the progression and development of tumorigenesis associated with NEK7 and NEK9 exhibit a similar ratio in both male and female patients. Furthermore, the analysis of different age groups indicated that all kinases (NEK6, NEK7, and NEK9) demonstrated a consistent expression profile across all age groups of patients, implying that individuals of any age have an equal likelihood of developing NEK-associated cancer malignancies. The detailed expression profile of NEK6, NEK7 and NEK9 associated with breast tissue is illustrated in Fig. 7 whereas expression profile of mentioned kinases in CESC (cervix), GBM (glioblastoma) alongside expression of isoform is provided in the supplementary file (Figure S10-S13). Differential expression of NEK6, NEK7 and NEK9 associated with breast tissues (BRCA) in various clinicopathological parameters. A Expression profile of NEK6 in different race groups. B Expression profile of NEK7 in different race based groups. C Expression profile of NEK9 in different race based groups. D Expression profile of NEK6 in different gender groups. E Expression profile of NEK7 in different gender groups. F Expression profile of NEK9 in different gender groups. G Expression profile of NEK6 in different age groups. H Expression profile of NEK7 in different age groups. I Expression profile of NEK9 in different age groups Correlation analysis of NEK7 with NEK6 and NEK9 in BRCA, CESC and GBM tissues Correlation analysis between two or more genes serves as a critical diagnostic and prognostic biomarker parameter, playing a pivotal role in the development and progression of tumorigenesis. Correlation analysis is a statistical technique used to measure the strength and direction of the linear relationship between two variables. In genetics, correlation analysis is often used to investigate the relationships between gene expression levels. A correlation coefficient, such as the Pearson correlation coefficient, is used to quantify the correlation between two genes. The Pearson correlation coefficient ranges from − 1 to + 1. A correlation coefficient of + 1 indicates a perfect positive correlation, meaning that the two genes are always expressed together. A correlation coefficient of −1 indicates a perfect negative correlation, meaning that as the expression of one gene increases, the expression of the other gene decreases. A correlation coefficient of 0 indicates no correlation between the two genes. The noteworthy observation emerged that in GBM tissues, NEK7 and NEK6 displayed a negative correlation, indicating that increased expression of NEK7 is associated with a decrease in the expression of NEK6. Conversely, in BRCA and CESC tissues, NEK7 exhibited a positive relationship with NEK6. Furthermore, NEK7 demonstrated a strong positive relationship with NEK9 across all three distinct cancer types. The correlation analysis unveiled various degrees of association between all three genes, suggesting the involvement of multiple NEK kinases in tumor progression and development. The Fig. 8 is illustrating the correlation analysis between NEK7, NEK6 and NEK9. Correlation analysis between NEK6, NEK7 and NEK9. Positive relationship observed between NEK7 and NEK9 in BRCA (A), CESC (B) and GBM (C) tissues. Similarly, NEK7 was in positive relationship with NEK6 in BRCA (D) and CESC (E) tissues, whereas negative relationship was observed between NEK7 and NEK6 in GBM (F) tissues Proteomics profiling The study leveraged the Human Protein Atlas database to access immunohistochemistry images of high NEK6, NEK7, and NEK9 expression in cancer and normal tissues of the breast, cervix, and brain. The immunohistochemistry expression levels were classified as not detected, high, medium, or low based on the intensity of staining. Analysis revealed a distinct and significant expression pattern in cancer tissues of the breast, cervix, and brain, as depicted in Fig. 9. The immunohistochemistry images depicted the expression of NEK6, NEK7, and NEK9 in cancer and normal tissues of the breast, cervix, and brain [39] Density functional theory (DFT) In this study, the reactivity and stability profile of TAJ4 was evaluated using DFTs studies. The analytical metrics utilized were LUMO/HOMO energy gap, global and local reactivity descriptors calculated using DFT/631-G* calculation setup [67]. The geometric parameters of TAJ4 is provided in Table 3. The tabulated data for the molecule TAJ4 includes the optimization energy, dipole moment, polarizability (α), HOMO energy, LUMO energy, and the HOMO-LUMO gap. The optimization energy is −2301.612, the dipole moment is 1.879, the polarizability is 554.966, the HOMO energy is −0.225 eV, the LUMO energy is −0.062 eV, and the HOMO-LUMO gap is 0.163 eV. The dipole moment and polarizability are crucial molecular properties that provide insights into the charge distribution and the molecule’s response to an external electric field. The HOMO and LUMO energies, along with the HOMO-LUMO gap, are essential for understanding the molecule’s electronic structure and its potential reactivity. The data suggests that TAJ4 exhibits a relatively low HOMO-LUMO gap, indicating a potential for electronic transitions at lower energy levels. This information is valuable for understanding the molecule’s electronic properties and its potential applications in various fields, including materials science and electronics. Table 3Optimization energies, HOMO and LUMO energies and their gap calculated in gas phase at B3LYP/6–31 G level of DFT calculationsCodesOptimization Energy (hartree)Dipole moment (debye)Polarizability (α)HOMO (eV)LUMO (eV)HOMO-LUMO (ΔeV)TAJ4−2301.6121.879554.966−0.225−0.0620.163 Optimization energies, HOMO and LUMO energies and their gap calculated in gas phase at B3LYP/6–31 G level of DFT calculations The highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) play a crucial role in the structure of a molecule. The determination of chemical reactivity in molecules can be achieved by analyzing the HOMO-LUMO band gap. A molecule with a higher HOMO-LUMO energy band gap has greater kinetic stability, less polarization, and decreased reactivity, making it classified as a hard molecule. A molecule with a reduced HOMO-LUMO energy band gap exhibits lesser stability, increased polarization, and more reactivity, making it classified as a soft molecule. In addition, the HOMO and LUMO orbitals were found to be located on both benzotriazole rings of TAJ4, indicating that electron transfer occurs in those specific regions. Figure 10 displays the optimized structures of the TAJ4 compound, together with the corresponding HOMO and LUMO orbitals. The optimized structures and HOMO, LUMO orbitals of TAJ4 The tabulated in Table 4 for the molecule TAJ4 includes the chemical potential (µ), electronegativity (X), hardness (ƞ), softness (S), and electrophilicity index (ω). The chemical potential is −0.144 eV, the electronegativity is 0.144 eV, the hardness is 0.082 eV, the softness is 6.135 eV-1, and the electrophilicity index is 0.126 eV. Table 4Global reactivity descriptorsCodesChemical Potential µ (eV)Electronegativity X (eV)Hardness ƞ (eV)softness S (eV-1)Electrophilicity index ω (eV)TAJ4−0.1440.1440.0826.1350.126Hardness: η = 1/2(ELUMO - EHOMO); Softness: S = 1/2η; Electronegativity: χ = −1/2(ELUMO + EHOMO); Chemical potential: µ = - χ; Electrophilicity index: ω = µ/2η Global reactivity descriptors Hardness: η = 1/2(ELUMO - EHOMO); Softness: S = 1/2η; Electronegativity: χ = −1/2(ELUMO + EHOMO); Chemical potential: µ = - χ; Electrophilicity index: ω = µ/2η These parameters offer valuable insights into the reactivity and stability of the molecule. The chemical potential provides information about the potential energy of the molecule, while electronegativity reflects its ability to attract electrons. The hardness and softness values are indicative of the molecule’s resistance to changes in electron density and its responsiveness to external perturbations, respectively. The electrophilicity index offers insights into the molecule’s tendency to accept electrons during chemical reactions. The result suggested that the compound TAJ4 has high electrophilicity index which indicates the power of a molecule to accept electrons. Molecular docking analysis The docking analysis revealed a robust molecular interaction between TAJ4 and NEK2, with a binding energy of −11.9 kJ/mol, as detailed in Table 5. This signifies the potential of the newly synthesized derivative as a promising therapeutic agent for cancer treatment. Table 5Molecular interactions of TAJ4 with 6 distinct proteinProteinPDB IDCodeDocking score kcal/molHydrogen bondforming residuesHydrophobicinteractionsNEK22W5ATAJ4−11.9LYS143,SER201MET183, PRO180,PHE160, ASP198, TYR182Dabrafenib(standard)−7.6ASN245,THR249GLU246, ARG235, PHE233NEK72WQNTAJ4−9.6ASN166,LYS163ASP179, ASP118, ALA165,PHE168, LYS63Dabrafenib(standard)−8.3ASP118,ARG121,GLU112,ASP179,ALA114ALA165, PHE168, ALA61NEK93ZKETAJ4−6.6ASN61ALA39, LYS36, PHE62, ILE57Dabrafenib(standard)−0.7NoNoTP533DCYTAJ4−7.8ARG10,ARG203LYS18, VAL229, GLY199Dabrafenib(standard)−0.0NoNoNF-KAPPA-B1NFITAJ4−9.3NoASP223, GLU222, PRO275, PHE239, GLU225, LYS 28Dabrafenib(standard)−8.4THR164, ARG174NoCaspase-33DEITAJ4−8.1ARG207,SER209OCS163, PHE256Dabrafenib(standard)−5.5LYS138, ASP146, ARG147No Molecular interactions of TAJ4 with 6 distinct protein MET183, PRO180, PHE160, ASP198, TYR182 Dabrafenib (standard) ASP179, ASP118, ALA165, PHE168, LYS63 Dabrafenib (standard) ASP118,ARG121,GLU112, ASP179,ALA114 Dabrafenib (standard) Dabrafenib (standard) Dabrafenib (standard) Dabrafenib (standard) The significance of the bindings lies in their ability to reveal the strength of molecular interactions and the potential therapeutic implications for cancer treatment. In the context of molecular docking, the binding affinity between a newly synthesized compound and specific proteins, such as NEK2, NEK7, and NEK9, provides crucial insights into the potential efficacy of the compound as a therapeutic agent. The binding energy of −10.0 kJ/mol observed between TAJ4 and NEK2 indicates a strong molecular interaction, suggesting the potential for TAJ4 to serve as a novel therapeutic agent against cancer. This finding underscores the importance of understanding the molecular interactions between compounds and target proteins, as it can guide the development of effective treatments and interventions for various diseases, including cancer. By elucidating the specific molecular interactions and binding affinities, molecular docking studies contribute to the identification and optimization of potential drug candidates, thereby advancing the field of drug discovery and development. The significance of these bindings extends to their potential impact on the development of targeted therapies and personalized medicine, offering new avenues for combating complex diseases such as cancer. Interpretation of molecular interactions of TAJ4 with targeted proteins The molecular docking offers a detailed analysis of the molecular interactions between a compound, TAJ4, and various proteins, as well as a comparison with the standard compound Dabrafenib. The significance of each interaction was determined by the docking score, which reflects the binding affinity, and the specific residues involved in hydrogen bonding and hydrophobic interactions. The docking score of −11.9 kcal/mol indicates a strong binding affinity between TAJ4 and NEK2, which is higher than that of the standard Dabrafenib (−7.6 kcal/mol). The hydrogen bond forming residues LYS143 and SER201, along with hydrophobic interactions involving MET183, PRO180, PHE160, ASP198, and TYR182, suggest a stable and specific interaction that could inhibit NEK2 activity, potentially impacting cell cycle regulation and cancer progression. The analysis showed that the synthesized compound may act as a potent NEK2 inhibitor. The presumed 2D and 3D interaction of TAJ4 with NEK2 is shown in Fig. 11(A). Furthermore, the synthesized compound exhibit potential interaction with NEK7 protein with a docking score of −9.6 kcal/mol, TAJ4 shows a significant affinity for NEK7, although slightly less than Dabrafenib (−8.3 kcal/mol). In Fig. 11(B), the 2D and 3D interaction between compound and NEK7 showed that ASN166 and LYS163 forms conventional hydrogen bond with shorter bond length. Similarly, ASP179 and ASP118 forms pi-anion linkage, while ALA165 and PHE168 forms pi-alkyl and pi-sigma interactions, which enables the compound to bind within the active pocket of NEK7 protein. These interactions indicate that TAJ4 could effectively bind and possibly modulate NEK7 function, which is involved in mitotic spindle formation. Moreover, TAJ4 exhibits a moderate docking score of −6.6 kcal/mol, which is considerably stronger than Dabrafenib’s negligible interaction (−0.7 kcal/mol). The single hydrogen bond with ASN61 and hydrophobic contacts with residues like PHE62 suggest a potential for TAJ4 to influence NEK9, which plays a role in cell cycle regulation and checkpoint activation. 2D and 3D binding interaction as shown in Fig. 11 (C) revealed that amino acid residue ASN61 forms conventional hydrogen bond with a shorter bond length of 2.9 angstroms. ALA39 and LYS36 pi-alkyl, PHE62 pi-pi T-shaped while ILE57 forms pi-sigma interaction respectively, which favors the binding of compound. The Putative binding orientation of compound TAJ4 within activation loop of various enzymes. A The predicted 2D and 3D binding mode of Benzotriazole (TAJ4) against NEK2. B The predicted 2D and 3D binding mode of Benzotriazole (TAJ4) against NEK7. C The predicted 2D and 3D binding mode of Benzotriazole (TAJ4) against NEK9. D The predicted 2D and 3D binding mode of Benzotriazole (TAJ4) against TP53. E The predicted 2D and 3D binding pose of Benzotriazole (3) against NF-KAPPA-B P65. F The predicted 2D and 3D binding mode of Benzotriazole (TAJ4) against Caspase-3 The molecular interactions between the synthesized compound and TP53 is shown in Fig. 11(D), the docking score of −7.8 kcal/mol for TAJ4 indicates a good binding affinity with amino acid residues of TP53, a key tumor suppressor protein, compared to no interaction with Dabrafenib. Hydrogen bonds with ARG10 and ARG203, along with hydrophobic interactions, suggest that TAJ4 could modulate TP53’s activity, potentially affecting its role in DNA repair and apoptosis. The predicted 2D and 3D binding pose of Benzotriazole (3) against NF-KAPPA-B P65 is shown in Fig. 11(E). TAJ4 docking score of −9.3 kcal/mol is superior to that of Dabrafenib (−8.4 kcal/mol), but the lack of hydrogen bonds suggests a different binding mode. There was scarcity of conventional hydrogen bond between the amino acid residues and TAJ4 compound. However, the engagement of amino acid residues via hydrophobic interactions was proven substantial player in maintaining the active conformation of compound within active pocket. Amino acid residue GLU225 forms pi-cation, GLU222 and ASP223 carbon hydrogen bond, while remaining residues of active site including PHE239 and PRO275 develop pi-pi T-shaped and pi-alkyl interactions respectively. The hydrophobic interactions with residues such as ASP223 and PHE239 could still enable TAJ4 to affect NF-KAPPA-B’s role in immune and inflammatory responses. The Fig. 11(F) is highlighting the presumed 2D and 3D binding pose of Benzotriazole (TAJ4) inside activation loop of Caspase-3. With a docking score of −8.1 kcal/mol, TAJ4 shows a stronger interaction with caspase-3 than Dabrafenib (−5.5 kcal/mol). The Docking analysis also shows that there is potent interaction between compound and caspase-3 with binding energy − 8.1 kcal/mol. Amino acid residues ARG207 and SER209 forms conventional hydrogen bond, PHE256 pi-sigma and OCS163 forms carbon hydrogen bonds respectively. Hydrogen bonds with ARG207 and SER209, along with hydrophobic interactions, suggest that TAJ4 could influence the proteolytic activity of caspase-3, which is crucial for apoptosis. In summary, TAJ4 demonstrates strong binding affinities and specific interactions with several key amino acid residues of targeted proteins involved in cancer progression and cell cycle regulation. The docking scores and molecular interactions suggest that TAJ4 has the potential to act as a multi-targeted therapeutic agent, with the possibility of modulating various pathways relevant to cancer treatment. The comparison of binding affinity with Dabrafenib highlights TAJ4’s potential advantages in certain interactions, which could be explored further in the development of targeted cancer therapies. Molecular dynamic simulations The present investigation employed Molecular Dynamics (MD) simulations to assess the conformational stability of the protein-ligand complex and the apo protein. The root mean square deviation (RMSD) and root mean square fluctuation (RMSF) were utilized to estimate the time-dependent trajectories of the apo protein, ligand (TAJ4), and protein-ligand complex. For MD simulations, the protein-ligand conformation with the predicted potential binding affinity by molecular docking was retrieved. To this end, periodic boundary conditions were applied to simulate the NEK2-TAJ4 complex and the NF-KAPPA-B-TAJ4 complex, and the strength of molecular interactions was evaluated. The protein-ligand complex (NEK2-TAJ4 complex) exhibited sustained interactions, as illustrated in Fig. 12(a), with an average value of 2.53Å. The structure of the complex remained stable throughout the duration of the simulation. The average RMSD for the ligand molecule TAJ4 was 3.20 Å, suggesting that its conformation remained relatively stable throughout the simulation. As a whole, the RMSD values indicate that the system maintained structural integrity and equilibrium throughout the duration of the simulation. Nevertheless, slight variations in equilibration indicated that the ligand molecule and amino acid residues underwent structural modifications at 300 K. For the purpose of elucidating the structural stability of NEK2 protein amino acid residues, the RMSF trajectory depicted in Fig. 12(b) was computed. A mean RMSF of 0.98Å indicated that amino acid residues maintained their stability and demonstrated minimal flexibility, thus facilitating strong interactions between ligands and proteins. a Root mean square deviation (RMSD) trajectories of TAJ4, NEK2, and NEK2-TAJ4 complex (b) The RMSF trajectory of NEK2 exhibits the protein's flexibility. c Time-dependent plot of the Solvent Accessible Surface Area (SASA) of the NEK2 protein. d The trajectory of the Radius of Gyration (Rg) of the NEK2 protein over time The SASA plot of NEK2 displays peaks that correspond to the areas of the protein that are more readily accessible to solvent molecules, as depicted in Fig. 12(c). This observation implies that certain specific regions demonstrate a greater level of adaptability and are not intensively populated. The portions that are exposed have the potential to undergo substantial conformational changes, which could have an impact on the functionality of the protein and its interactions with other molecular entities. On the other hand, the presence of valleys in the SASA plot indicates the existence of buried residues that are firmly compacted and have minimal exposure to solvents. These areas have a crucial role in maintaining the stability and facilitating the folding dynamics of the protein, as they constitute the fundamental structure of the molecule. The Rg analysis illustrated in Fig. 12(d) provides significant insights into the protein conformation’s compactness. Within the plot, the presence of trough regions signifies the frequency of time intervals in which the protein assumes a shape that is more globular and well-folded. The observed regions in the apo protein are suggestive of stable conformations, characterized by the dense packing of individual residues, resulting in a compact and well-structured arrangement. On the other hand, the presence of crest regions in the Rg plot indicates the occurrence of distorted conformations, characterized by the presence of more flexible regions within the protein. The observed crest sections appear to be associated with regions characterized by reduced stability or conformational alterations, resulting in enhanced flexibility and the enlargement of the protein’s structure. Through the examination of the Rg plot, a more comprehensive comprehension of the temporal or contextual variations in the protein’s overall compactness can be attained. This analytical approach holds significant value in the examination of protein structural stability and dynamics, facilitating the elucidation of crucial insights into their functional behavior. Furthermore, an analysis of the amino acid residues that are implicated in the formation of hydrogen bonds can be employed to ascertain the electrostatic interactions between the ligand molecule TAJ4 and the NEK2 protein. The examination of Table 6 unveiled the significant contribution of particular NEK2 residues, namely GLN187, LYS143, THR175, GLN221, and ASN189, in the formation of a hydrogen bond network with the TAJ4 side atoms. The aforementioned interactions play a substantial role in the formation of a very stable protein-ligand complex, as depicted in Fig. 13 (D). The detailed study of hydrogen bond dynamics further enlightens our understanding of the dynamic forces governing the interaction between the ligand and protein, providing valuable insights into the complex’s conformational stability. Furthermore, the total number of hydrogen bond acceptor and donor observed during MD simulation is tabulated in Table 6. Table 6MMGBSA analysis of NEK2-TAJ4, NF-KAPPA-B-TAJ4 complex and hydrogen bond analysis of TAJ4-NEK2 complexMMGBSA analysisHydrogen Bond analysisHydrogen bond DonorHydrogen bond AcceptorEnergy contributorNEK2-TAJ4 complexNF-KAPPA-B-TAJ4 complexGLN187-SideTAJ4-SideLYS143-SideTAJ4-SideΔEVDW (kcal/mol)−35.20−23.53TAJ4-SidePHE176-MainΔEel (kcal/mol)−1.55−3.51TAJ4-SideTHR175-MainΔEGB (kcal/mol)9.716.05THR175-SideTAJ4-SideΔEsurf (kcal/mol)−2.35−2.31GLN221-SideTAJ4-SideΔG (kcal/mol)−29.39−23.3ASN189-SideTAJ4-Side MMGBSA analysis of NEK2-TAJ4, NF-KAPPA-B-TAJ4 complex and hydrogen bond analysis of TAJ4-NEK2 complex A Evolution of RMSD pattern for C-alpha atoms (blue colored trajectory) and protein ligand complex (red colored trajectory) (B) RMSF of NF-KAPPA-B amino acid residues (C) Contact map profile of protein-ligand complex (D) Plot represents number of hydrogen bond interactions of NEK2 protein with TAJ4 Second best conformation of TAJ4 was against NF-KAPP-B protein which is one of crucial regulator of development and progression of cancer cells. The top ranked conformation obtained from molecular docking was subjected to MD simulation for integrating molecular behavior of protein-ligand complex. It was notable that Apo protein NF-KAPPA-B exhibited slight perturbation but fluctuations remained below 3.5 angstroms. RMSD trajectory of protein remained stable till 20ns which got fluctuated and raised up to 3.5 angstroms and got equilibrated. As simulation progressed, fluctuation got stable and dropped to 3 angstroms at end of simulation. Furthermore, Protein-ligand complex exhibited contrary behavior to Apo protein. Interestingly, protein-complex demonstrated significant stability pattern with RMSD trajectory remained stable through the MD simulation. The average RMSD for protein-ligand complex was 2.3 angstroms which quite acceptable. These stability pattern of protein-ligand complex was due to establishment of stronger hydrophobic and hydrophilic interactions between TAJ4 and active site residues. Particularly, CYS163 was engaged hydrogen bonding for approximately 50% of simulation time. In addition, TYR204, TRP206, ARG207 and PHE256 was significantly engaged in hydrophobic interactions which is signifying the stability of protein-ligand complex. Furthermore, residue wise fluctuations of targeted protein was evaluated through RMSF metric. It was notable that all residues remained stable and fluctuations were found to be under acceptable limit. Interestingly, amino acid residues in contact with TAJ4 exhibited least fluctuations which lend enough testimony on stability of protein-ligand complex. The detailed evolution of RMSD pattern for C-alpha atoms of Apo protein, protein ligand complex, RMSF of amino acid residues and contact map is illustrated in Fig. 13 (A, B and C). The MMGBSA analysis of the NEK2-TAJ4 and NF-KAPPA-B-TAJ4 complexes, as presented in Table 6, provides valuable insights into the energetics and stability of these protein-ligand interactions. The energy contributors, including ΔEVDW, ΔEel, ΔEGB, ΔEsurf, and ΔG, offer a comprehensive view of the binding free energies and the individual components contributing to the overall stability of the complexes. In the NEK2-TAJ4 complex, the ΔEVDW of −35.20 kcal/mol and ΔEel of −1.55 kcal/mol indicate a substantial contribution from van der Waals interactions, while the solvation free energy (ΔEGB) and surface energy (ΔEsurf) further contribute to the overall binding free energy (ΔG) of −29.39 kcal/mol. Similarly, in the NF-KAPPA-B-TAJ4 complex, the energy contributors demonstrate a comparable pattern, albeit with slightly lower values, suggesting a favorable binding affinity with a ΔG of −23.3 kcal/mol. The MMGBSA is crucial in understanding the thermodynamic aspects of protein-ligand interactions. These methods allow for the decomposition of the free energy of binding into enthalpic and entropic contributions, providing a detailed understanding of the molecular recognition process. The EMM term, encompassing internal energies, electrostatic interactions, and van der Waals forces, along with solvation free energy contributions, collectively influence the overall stability and binding affinity of the complexes. Furthermore, the comparison between the NEK2-TAJ4 and NF-KAPPA-B-TAJ4 complexes reveals distinct energetic profiles, indicating specific molecular interactions and binding modes unique to each complex. The differences in energy contributors highlight the diverse nature of protein-ligand interactions and underscore the significance of understanding the underlying energetics for rational drug design and optimization. Overall, the MMGBSA analyses presented in Table 6 offer a comprehensive assessment of the energetics of the NEK2-TAJ4 and NF-KAPPA-B-TAJ4 complexes, providing valuable data for elucidating the molecular mechanisms of binding and informing the development of potential therapeutic agents targeting these protein targets. Hirshfeld surface analysis Intermolecular interactions of the compound and Hirshfeld surface (HS) was plotted using Hirshfeld surface analysis technique employed in crystal explorer. HS surface was categorized with blue and white colored regions as shown in supplementary file (Figure S14). The white colored region indicate contacts with distances equal to the sum of van der Waals radii, and the red and blue colors indicate distances shorter (in close contact) or longer (distinct contact) than the van der Waals radii, respectively. In addition, The comprehensive two-dimensional fingerprint plot, depicted in supplementary file (Figure S15), delineates various interactions, including H … H, H … C/C … H, H … O/O … H, H … N/N … H, C … N/N … C, C … C, and N … N in addition with their contribution toward HS surface is sufficiently elaborated in supplementary file (Table S1). Conclusion In conclusion, the synthesis of the benzotriazole derivative TAJ4 has yielded a compound with remarkable potential as a novel therapeutic agent for cancer treatment. Through biological evaluation and in-silico investigations, TAJ4 has demonstrated substantial inhibitory potential against various cancer proteins, particularly exhibiting superior efficacy compared to standard doxorubicin and cisplatin, especially in HeLa cell lines. Additionally, differential expression analysis has identified NEK kinases as potential diagnostic and prognostic biomarkers, further emphasizing the significance of TAJ4. DFT studies, molecular docking, and MD simulation studies have collectively highlighted TAJ4’s reactive nature, strong binding interactions with targeted proteins, and significant stability of the protein-ligand complex over time. The compound’s reactivity profile has been further validated through Hirshfeld surface analysis. These findings underscore the promising potential of TAJ4 as an anticancer agent and warrant further in-vivo studies to fully explore its therapeutic effects. Supplementary Information Supplementary Material 1. Acknowledgements This research was funded by King Khalid University, researchers supporting project number [RGP.02-297-44], King Khalid University, Riyadh, Saudi Arabia. Authors’ contributions The study plan was designed and supervised by S.A.E for M.A. All experimental work was carried out by M.A. & R.U. Methodology and validation was done by A.G.A, P.A.C, T.Q and M.H. Z.H. & M.A. contributed in manuscript writing and in-vitro studies. Funding The authors extend their appreciation to researchers supporting project number [RGP.02-297-44], King Khalid University, Riyadh, Saudi Arabia, for funding this research. The funding body played potential role in the design of the study, purchasing, sample characterization, analysis, interpretation of data, and in writing the manuscript. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.